A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer
Latest Information Update: 21 Jun 2024
At a glance
- Drugs Nadofaragene-firadenovec (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors FKD Therapies
- 06 May 2024 Results (n=35) evaluate the utility of uMRD to identify molecular response to Nadofaragenein patients with high-grade (HG) BCG-refractory or relapsed NMIBC, presented at the 119th Annual Meeting of the American Urological Association
- 27 Jan 2024 Primary endpoint (Incidence of High Grade-Recurrence Free Survival at 360 Days) has been met, as per results presented at the 2024 Genitourinary Cancers Symposium.
- 27 Jan 2024 Results assessing the utility of uMRD to identify molecular response to Nadofaragene in patients with high-grade BCG-refractory or relapsed NMIBC, presented at the 2024 Genitourinary Cancers Symposium.